Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group
about
sameAs
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersGeneralised anxiety disorderCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersQTc prolongation by psychotropic drugs and the risk of Torsade de PointesGeneralised anxiety disorder.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Pharmacological treatment for generalized anxiety disorder in adults: an update.Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity.Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Opipramol.Opipramol dihydro-chloride.Escitalopram in the treatment of generalized anxiety disorder.The sigma-1 receptor: roles in neuronal plasticity and diseaseNorbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 Subtype-Selective LigandsThe diagnosis and treatment of generalized anxiety disorder.Attention modification program in individuals with generalized anxiety disorderStandardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales.sigma-1 receptors in major depression and anxiety.Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder.The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET).Opipramolium fumarate.Opipramol dipicrate.Opipramol improves subjective quality of sleep the night prior to surgery: confirmatory testing of a double-blind, randomized clinical trial.The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm".An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.Amelioration of Pentylenetetrazole-Induced Seizures by Modulators of Sigma, N-Methyl-D-Aspartate, and Ryanodine Receptors in Mice.Crystal Structure, Spectral Studies, and Hirshfeld Surfaces Analysis of 5-Methyl-5H-dibenzo[b,f]azepine and 5-(4-Methylbenzyl)-5H-dibenzo[b,f]azepine
P2860
Q22305681-EC90DDAC-93C6-45D5-A541-286978507C23Q26863288-2D75F983-0AD7-4A5A-AF07-947470556249Q27009995-61CF19AD-2D12-4DE5-A4C4-CD4BE06CD670Q27015763-C3950663-7BF9-482C-8D0F-831567C3E6C0Q33446789-3FAEFD3F-CFBA-469C-92ED-F661C7F06058Q34465555-A493CC49-12D1-4446-BD9A-73A14FD2DF0AQ34484276-8682E601-505C-4A8D-A34B-A1AD72A6BF69Q34555731-B0E4C792-5D0F-450D-B138-C99B407CFED3Q34795242-C0F13C53-800E-48AC-9247-6382C3E4A61FQ34865036-08126780-5543-47BF-A380-71DE7497DE5AQ35152657-8E35B678-6D1D-45B8-A887-04E62167EAE2Q35638081-9353DD38-EF3C-4E2F-AA6B-D7EA516217F3Q36198579-AD6D8C6B-18EB-4177-9582-A83EBB28BAC3Q36653400-2DB8217C-821A-4DB5-9E90-2A01DD421250Q36738536-9A06E6AB-877D-4B82-AA68-DD82EB48E659Q36837462-FF1D16C8-C674-4D8A-9925-1E2EE488012FQ37104120-B87AE448-7AA9-4CCD-8634-4C1D8ECC8D6AQ37229333-59600386-DBB6-48D1-866B-79B4B278934CQ37546082-3D192227-C345-4D17-A270-6B73B1322084Q38031324-6197D9C5-7DA5-4287-B14C-74C875EA945AQ38166977-7B72CF0A-99C8-45BC-98FC-B5698F78F649Q38814952-360092FF-B59A-4843-A4CD-D0EEA3AC8582Q41360539-607144BF-2E1A-4ECB-8ACD-4B94D8AFF6DFQ44044318-F302740E-120F-4131-8C6F-245BE4F95CE8Q45159165-DA9824D3-035F-43A5-A8D7-CD83E3A192D0Q46913592-849491C1-C6A1-4CA4-ABE8-34BADC8E37BCQ47845016-2FAEB741-5A5D-4314-8E71-88EC96F6D9B3Q54966162-2670C59E-E047-45D8-AFFE-47C003C7FD7CQ59055343-A980A9D5-06F2-434D-89A5-A4497EA2A1B3
P2860
Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Opipramol for the treatment of ...... ng an alprazolam-treated group
@ast
Opipramol for the treatment of ...... ng an alprazolam-treated group
@en
Opipramol for the treatment of ...... ng an alprazolam-treated group
@nl
type
label
Opipramol for the treatment of ...... ng an alprazolam-treated group
@ast
Opipramol for the treatment of ...... ng an alprazolam-treated group
@en
Opipramol for the treatment of ...... ng an alprazolam-treated group
@nl
prefLabel
Opipramol for the treatment of ...... ng an alprazolam-treated group
@ast
Opipramol for the treatment of ...... ng an alprazolam-treated group
@en
Opipramol for the treatment of ...... ng an alprazolam-treated group
@nl
P2093
P1476
Opipramol for the treatment of ...... ng an alprazolam-treated group
@en
P2093
P356
10.1097/00004714-200102000-00011
P407
P577
2001-02-01T00:00:00Z